At DeepCure, we are focused on discovering and developing novel small-molecule drugs focused on areas of unmet medical need.
Our technology is indication-agnostic, which gives us the unique advantage of being opportunistic with our target selection strategy. Our first step in identifying targets with the best fit was to decide on unmet medical need and unlocking unexplored chemical space, allowing for multi-parameter optimization.
We are developing multiple pipeline candidates across different “undruggable” classes, ranging from polypharmacology programs, to protein-protein interactions, and previously “impossible” specificity challenges.
DNA Damage Response
Cell Death Regulation
Clear-Cell Ovarian Cancer
Pancreatic Ductal Adenocarcinoma